Braemar (Minneapolis) has introduced the DL900, a digital Holter monitor. The monitor weighs 1.75 ounces, and has extended recording time of up to seven days. A newly designed, custom analog IC for signal acquisition is the technology platform for the advanced capabilities of the DL900. The device combines high-speed USB transfer capability with the ability to use a removable SD memory card. The DL900 provides high-resolution recordings as well as high sampling rate options suitable for both clinical and research applications. A programmable pacemaker detection capability provides the clinician with additional data. Braemar makes cardiac monitoring devices.

Calypte Biomedical (Lake Oswego, Oregon) reported the launch of Calypte Life Sciences. Calypte Life Sciences offers a broad range of recombinant proteins and antigens, as well as proprietary reagents, buffers and other specialty products to researchers and institutions seeking to develop and optimize immunodiagnostic assay systems. Calypte Life Sciences products are being distributed through a new on-line catalog (, as well as through Calypte's worldwide network of distributors. Calypte makes HIV diagnostic tests.

Perceptive Informatics (Boston), the technology subsidiary of Parexel International, said that it has integrated its medical imaging technology with the functionality of DigiView, a specialized image management and reporting system provided by Digisonics, to offer clients expanded capabilities for cardiac function assessment in clinical studies. The system provides electronic review, analysis, reporting, and archiving of medical images related to cardiac function assessment. Cardiac function assessment is required for a broad range of therapeutic area research, including cardiology, oncology, central nervous system, and metabolism/endocrinology studies. Parexel said its technology division, Perceptive Informatics, combines clinical knowledge, quality and regulatory experience with advanced technology to decrease time to market, risk and cost associated with clinical trials.

Royal Philips Electronics (Amsterdam, the Netherlands) reported the results of a study confirming the benefit of using CPR sensing and recording technology to improve CPR performance. Results drawn from medical professionals participating in the Resuscitation with Actual Performance Integrated Debriefing (RAPID) trials were published in the study, "Improving In-Hospital Cardiac Arrest Process and Outcomes using Performance Debriefing." The Philips HeartStart MRx with Q-CPR measurement and feedback was used to record resuscitation performance during actual cardiac arrest events. Medical professionals then participated in weekly debriefing sessions to review transcripts from the prior week's resuscitations and analyze CPR performance, including chest compression rate and depth, ventilation rate and undesired pauses in compressions. Royal Philips Electronics makes medical diagnostic imaging and patient monitoring systems.

Veridex (Raritan, New Jersey) said that its licensing collaborator, Laboratory Corporation of America Holdings (LabCorp; Burlington, North Carolina), has launched a new gene methylation test for prostate cancer. The new assay uses the biological specificity of "DNA methylation" in prostate cancer, detecting the methylation of the gene GST-Pi. Methylation is a modification of DNA that occurs primarily in cancer. Veridex is making the methylation markers in this tissue assay, GST-Pi, along with other markers, for a urine-based screening test for prostate cancer. Veridex makes cancer diagnostic products.

ViraCor Laboratories (Kansas City, Missouri) reported the launch of a new enterovirus test that quickly pinpoints the virus. The molecular test is designed to quickly and accurately detect the more than 70 known strains of enterovirus, giving physicians the information they need to treat patients appropriately. It also allows them to determine and track the severity of an infection by measuring a patient's viral load. The enterovirus test is one of 21 infectious disease tests ViraCor provides to healthcare professionals who care for patients with compromised immune systems, including adults and children who are undergoing transplants or battling cancer.

Xoft (Sunnyvale, California) said it has received FDA clearance for applicators to be used with the Axxent electronic brachytherapy system for the treatment of endometrial cancer. Previously cleared for accelerated treatment of early stage breast cancer, the Axxent system, a technology platform designed to deliver localized, non-radioactive, isotope-free radiation treatment in minimally-shielded clinical settings, also recently received expanded FDA clearance for use in the treatment of other cancers or conditions where radiation therapy is indicated. As a platform technology, the Axxent electronic brachytherapy system is designed to address a variety of oncological and non-oncological indications. Delivering electronic, X-ray-based radiation treatment, the proprietary Axxent treatment platform can be used in virtually any clinical setting under the supervision of a radiation oncologist. Xoft makes new technologies for the practice of radiation oncology through electronic brachytherapy, which utilizes proprietary miniaturized X-ray tube technology.